In favor of theragnostic perspectives, there was a significant reduction of uptake in the GRPR-rich mouse pancreas for both [68Ga]NeoBOMB1 and [177Lu]NeoBOMB1 with rapidly increasing tumor-to-pancreas ratios for the 200 pmol dose [20]. This evidence concerns the gene GRPR and neoplasm.